NASDAQ:XNCR - Xencor Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $36.08 -0.38 (-1.04 %) (As of 02/20/2019 02:47 AM ET)Previous Close$36.46Today's Range$35.46 - $36.905052-Week Range$24.13 - $48.38Volume140,159 shsAverage Volume177,017 shsMarket Capitalization$2.03 billionP/E Ratio-34.36Dividend YieldN/ABeta1.6 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers MOR208, an antibody drug, that in Phase III clinical trial to treat non-Hodgkin lymphomas, as well as in Phase II clinical trial for chronic lymphocytic leukemia; and AMG424, a bispecific CD38 x CD3 preclinical candidate for various myeloma. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104, which are in preclinical Phase. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. to develop and commercialize bispecific and other Fc engineered antibody drug candidates using its proprietary XmAb technologies and drug candidates, as well as MorphoSys Ag to develop and commercialize bispecific antibody product candidates; license agreement with Amgen Inc. to develop and commercialize bispecific antibody product candidates; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. Xencor, Inc.was founded in 1997 and is headquartered in Monrovia, California. Receive XNCR News and Ratings via Email Sign-up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XNCR Previous Symbol CUSIPN/A Webwww.xencor.com Phone626-305-5900Debt Debt-to-Equity RatioN/A Current Ratio5.52 Quick Ratio5.52Price-To-Earnings Trailing P/E Ratio-34.36 Forward P/E Ratio-23.43 P/E GrowthN/A Sales & Book Value Annual Sales$35.71 million Price / Sales56.82 Cash FlowN/A Price / Cash FlowN/A Book Value$6.01 per share Price / Book6.00Profitability EPS (Most Recent Fiscal Year)($1.05) Net Income$-48,920,000.00 Net MarginsN/A Return on Equity-13.69% Return on Assets-11.76%Miscellaneous Employees114 Outstanding Shares56,234,000Market Cap$2.03 billion OptionableOptionable Xencor (NASDAQ:XNCR) Frequently Asked Questions What is Xencor's stock symbol? Xencor trades on the NASDAQ under the ticker symbol "XNCR." How were Xencor's earnings last quarter? Xencor Inc (NASDAQ:XNCR) announced its quarterly earnings results on Monday, November, 5th. The biopharmaceutical company reported $0.05 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.52) by $0.57. The biopharmaceutical company earned $29.04 million during the quarter. View Xencor's Earnings History. When is Xencor's next earnings date? Xencor is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Xencor. What price target have analysts set for XNCR? 7 equities research analysts have issued twelve-month price objectives for Xencor's shares. Their predictions range from $28.00 to $56.00. On average, they expect Xencor's share price to reach $41.50 in the next year. This suggests a possible upside of 15.0% from the stock's current price. View Analyst Price Targets for Xencor. What is the consensus analysts' recommendation for Xencor? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xencor. What are Wall Street analysts saying about Xencor stock? Here are some recent quotes from research analysts about Xencor stock: 1. Cantor Fitzgerald analysts commented, "we reiterate our Overweight rating and $40 Price Target. We believe that this announcement continues to show the value of their platform in a world where bi-specifics are becoming more important. Xencor announced a new partnership with Genentech on XmAb24306, which is a preclinical bispecific targeting IL-15 and IL-15 alpha and a 2 year research program to discover new IL-15 candidates. XNCR is up 5% in early trading. We think this deal continues to validate Xencor’s platform and gives them greater cash flexibility while still having their own portfolio of assets to develop." (2/5/2019) 2. According to Zacks Investment Research, "Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. " (12/20/2018) Has Xencor been receiving favorable news coverage? News articles about XNCR stock have been trending somewhat negative this week, InfoTrie reports. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Xencor earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future. Who are some of Xencor's key competitors? Some companies that are related to Xencor include Ionis Pharmaceuticals (IONS), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Nektar Therapeutics (NKTR), Loxo Oncology (LOXO), Marina Biotech (MRNA), Perrigo (PRGO), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Patheon (PTHN) and Alkermes (ALKS). Who are Xencor's key executives? Xencor's management team includes the folowing people: Dr. Bassil I. Dahiyat, Co-Founder, CEO, Pres & Director (Age 49)Mr. John J. Kuch, Sr. VP of Fin., CFO & Sec. (Age 60)Dr. John R. Desjarlais, Sr. VP of Research & Chief Scientific Officer (Age 55)Dr. Paul A. Foster, Sr. VP & Chief Medical Officer (Age 65)Mr. Charles Liles, Associate Director and Head of Corp. Communications & Investor Relations Who are Xencor's major shareholders? Xencor's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.38%), Northern Trust Corp (1.07%), Geode Capital Management LLC (0.98%), Dimensional Fund Advisors LP (0.71%), Rhenman & Partners Asset Management AB (0.39%) and Bank of New York Mellon Corp (0.37%). Company insiders that own Xencor stock include Bassil I Dahiyat, Bruce L A Carter, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Institutional Ownership Trends for Xencor. Which major investors are selling Xencor stock? XNCR stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, First Trust Advisors LP, Prudential Financial Inc., Bank of New York Mellon Corp, Two Sigma Advisers LP, MetLife Investment Advisors LLC, Squarepoint Ops LLC and New York State Common Retirement Fund. Company insiders that have sold Xencor company stock in the last year include Bassil I Dahiyat, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Insider Buying and Selling for Xencor. Which major investors are buying Xencor stock? XNCR stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, BlackRock Inc., 361 Capital LLC, Tekla Capital Management LLC, Victory Capital Management Inc., Geode Capital Management LLC, D. E. Shaw & Co. Inc. and Citigroup Inc.. View Insider Buying and Selling for Xencor. How do I buy shares of Xencor? Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Xencor's stock price today? One share of XNCR stock can currently be purchased for approximately $36.08. How big of a company is Xencor? Xencor has a market capitalization of $2.03 billion and generates $35.71 million in revenue each year. The biopharmaceutical company earns $-48,920,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. Xencor employs 114 workers across the globe. What is Xencor's official website? The official website for Xencor is http://www.xencor.com. How can I contact Xencor? Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected] MarketBeat Community Rating for Xencor (NASDAQ XNCR)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 351 (Vote Outperform)Underperform Votes: 196 (Vote Underperform)Total Votes: 547MarketBeat's community ratings are surveys of what our community members think about Xencor and other stocks. Vote "Outperform" if you believe XNCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XNCR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/20/2019 by MarketBeat.com StaffFeatured Article: What are the benefits of a balanced fund?